These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 9555863)

  • 1. IDL composition and angiographically determined progression of atherosclerotic lesions during simvastatin therapy.
    Sutherland WH; Restieaux NJ; Nye ER; Williams MJ; de Jong SA; Robertson MC; Walker HL
    Arterioscler Thromb Vasc Biol; 1998 Apr; 18(4):577-83. PubMed ID: 9555863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
    Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
    Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, open-label, comparative study of simvastatin plus diet versus diet alone on angiographic retardation of coronary atherosclerosis in adult Japanese patients: Japanese utilization of simvastatin therapy (JUST) study.
    Mizuno K; Nakamura H; Ohashi Y; Kaburagi T; Kitabatake A; Tochihara T; Hosoda S;
    Clin Ther; 2004 Jun; 26(6):878-88. PubMed ID: 15262458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of simvastatin and fenofibrate on the fatty acid composition of hypercholesterolaemic patients.
    Agheli N; Jacotot B
    Br J Clin Pharmacol; 1991 Oct; 32(4):423-8. PubMed ID: 1958434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness.
    Hodis HN; Mack WJ; Dunn M; Liu C; Liu C; Selzer RH; Krauss RM
    Circulation; 1997 Apr; 95(8):2022-6. PubMed ID: 9133510
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of triglyceride-rich lipoprotein families in the progression of atherosclerotic lesions as determined by sequential coronary angiography from a controlled clinical trial.
    Alaupovic P; Mack WJ; Knight-Gibson C; Hodis HN
    Arterioscler Thromb Vasc Biol; 1997 Apr; 17(4):715-22. PubMed ID: 9108785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of angiographically defined coronary artery disease to serum lipoproteins and apolipoproteins in young survivors of myocardial infarction.
    Hamsten A; Walldius G; Szamosi A; Dahlen G; de Faire U
    Circulation; 1986 Jun; 73(6):1097-110. PubMed ID: 3698244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two subpopulations of intermediate density lipoprotein and their relationship to plasma triglyceride and cholesterol levels.
    Meyer BJ; Caslake MJ; McConnell MM; Packard CJ
    Atherosclerosis; 2000 Dec; 153(2):355-62. PubMed ID: 11164424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Triglyceride- and cholesterol-rich lipoproteins have a differential effect on mild/moderate and severe lesion progression as assessed by quantitative coronary angiography in a controlled trial of lovastatin.
    Hodis HN; Mack WJ; Azen SP; Alaupovic P; Pogoda JM; LaBree L; Hemphill LC; Kramsch DM; Blankenhorn DH
    Circulation; 1994 Jul; 90(1):42-9. PubMed ID: 8026027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of long term cholesterol lowering on coronary atherosclerosis in patient risk factor subgroups: the Simvastatin/enalapril Coronary Atherosclerosis Trial (SCAT).
    Burton JR; Teo KK; Buller CE; Plante S; Catellier D; Tymchak W; Taylor D; Dzavik V; Montague TJ;
    Can J Cardiol; 2003 Apr; 19(5):487-91. PubMed ID: 12717482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
    Meyer BJ; Hammervold T; Rustan AC; Howe PR
    Lipids; 2007 Mar; 42(2):109-15. PubMed ID: 17393216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One year experience in the treatment of familial hypercholesterolaemia with simvastatin.
    Quiney J; Watts GF; Kerr-Muir M; Slavin B; Lewis B
    Postgrad Med J; 1992 Jul; 68(801):575-80. PubMed ID: 1437957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE; Walden CE; Hunninghake DB; Hill-Williams D; Knopp RH
    Am J Cardiol; 1995 Jul; 76(2):129A-135A. PubMed ID: 7604788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease.
    Steiner G; Schwartz L; Shumak S; Poapst M
    Circulation; 1987 Jan; 75(1):124-30. PubMed ID: 3791598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans.
    McPherson R
    Can J Clin Pharmacol; 1999; 6(2):85-90. PubMed ID: 10519734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia.
    Wakatsuki A; Okatani Y; Ikenoue N
    Atherosclerosis; 2000 May; 150(1):103-11. PubMed ID: 10781640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.
    Bocan TM; Krause BR; Rosebury WS; Lu X; Dagle C; Bak Mueller S; Auerbach B; Sliskovic DR
    Atherosclerosis; 2001 Jul; 157(1):97-105. PubMed ID: 11427208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of increasing doses of simvastatin on fasting lipoprotein subfractions, and the effect of high-dose simvastatin on postprandial chylomicron remnant clearance in normotriglyceridemic patients with premature coronary sclerosis.
    van Wijk JP; Buirma R; van Tol A; Halkes CJ; De Jaegere PP; Plokker HW; van der Helm YJ; Castro Cabezas M
    Atherosclerosis; 2005 Jan; 178(1):147-55. PubMed ID: 15585212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease.
    Tatami R; Mabuchi H; Ueda K; Ueda R; Haba T; Kametani T; Ito S; Koizumi J; Ohta M; Miyamoto S; Nakayama A; Kanaya H; Oiwake H; Genda A; Takeda R
    Circulation; 1981 Dec; 64(6):1174-84. PubMed ID: 7296792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease.
    Kroon AA; van Asten WN; Stalenhoef AF
    Ann Intern Med; 1996 Dec; 125(12):945-54. PubMed ID: 8967704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.